Skip to main content
Premium Trial:

Request an Annual Quote

Doug Farrell, David Block

Premium

Affymetrix has appointed Doug Farrell as its new vice president of investor relations. Farrell comes to Affymetrix from Aurora Biosciences, where he served as senior director of investor relations and corporate communications. Aurora was acquired by Vertex Pharmaceuticals in July.

 

David Block has been appointed executive vice president of Celera, and chief operating officer of Celera’s therapeutics business. Block comes to Celera from DuPont Pharmaceuticals, where he worked for 12 years, most recently serving as executive vice president for international operations.

At Celera, Block will oversee the development of its pharmaceutical business, coordinating the therapeutic program, and will oversee mergers and acquisitions, as well as directing alliances and licensing agreements with other companies.

Block replaces Peter Barrett, a co-founder of Celera who served as chief business officer and executive vice president. Barrett has accepted a position at Atlas Venture, a leading life sciences venture capital firm. Barrett will work with Jean-Francois Formela out of Atlas’ Boston office to lead investments in US life sciences companies.

Before founding Celera, Barrett moved PerkinElmer into life sciences, shepherding its acquisition of Applied Biosystems in 1993.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.